The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
Open accessAbstract
BACKGROUND: Injectable luteinizing hormone-releasing hormone agonists (e.g., leuprolide) are the standard agents for achieving androgen deprivation for prostate cancer despite the initial testosterone surge and delay in therapeutic effect. The efficacy and safety of relugolix, an oral gonadotropin-releasing hormone antagonist, as compared with those of leuprolide are not known. METHODS: In this phase 3 trial, we randomly assigned patients with advanced prostate cancer, in a 2:1 ratio, to receive relugolix (120 mg orally once daily) or leuprolide (injections every 3 months) for 48 weeks. The primary end point was sustained testosterone suppression to castrate levels (<50 ng per deciliter) through 48 weeks. Secondary end points included noninferiority with respect to the primary end point, castrate levels of testosterone on day 4, and profound castrate levels (<20 ng per deciliter) on day 15. Testosterone recovery was evaluated in a subgroup of patients. RESULTS: A total of 622 patients received relugolix and 308 received leuprolide. Of men who received relugolix, 96.7% (95% confidence interval [CI], 94.9 to 97.9) maintained castration through 48 weeks, as compared with 88.8% (95% CI, 84.6 to 91.8) of men receiving leuprolide. The difference of 7.9 percentage points (95% CI, 4.1 to 11.8) showed noninferiority and superiority of relugolix (P<0.001 for superiority). All other key secondary end points showed superiority of relugolix over leuprolide (P<0.001). The percentage of patients with castrate levels of testosterone on day 4 was 56.0% with relugolix and 0% with leuprolide. In the subgroup of 184 patients followed for testosterone recovery, the mean testosterone levels 90 days after treatment discontinuation were 288.4 ng per deciliter in the relugolix group and 58.6 ng per deciliter in the leuprolide group. Among all the patients, the incidence of major adverse cardiovascular events was 2.9% in the relugolix group and 6.2% in the leuprolide group (hazard ratio, 0.46; 95% CI, 0.24 to 0.88). CONCLUSIONS: In this trial involving men with advanced prostate cancer, relugolix achieved rapid, sustained suppression of testosterone levels that was superior to that with leuprolide, with a 54% lower risk of major adverse cardiovascular events. (Funded by Myovant Sciences; HERO ClinicalTrials.gov number, NCT03085095.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Scher, H. I., Morris, M. J., Stadler, W. M., Higano, C., Basch, E., Fizazi, K., Antonarakis, E. S., Beer, T. M., Carducci, M. A., Chi, K. N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.2702 · Cited by 1,654
Self-citationCornford, P., Bellmunt, J., Bolla, M., Briers, E., De Santis, M., Gross, T., Henry, A. M., Joniau, S., Lam, T. B., Mason, M. D., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.08.002 · Cited by 1,438
2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults
Greenland, P., Alpert, J. S., Beller, G. A., Benjamin, E. J., Budoff, M. J., Fayad, Z. A., Foster, E., Hlatky, M. A., Hodgson, J. M., Kushner, F. G., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.09.001 · Cited by 1,324
Androgen Deprivation Therapy for Prostate Cancer
Sharifi, N. (2005) · JAMA · doi:10.1001/jama.294.2.238 · Cited by 1,083
Bubley, G. J., Carducci, M., Dahut, W., Dawson, N., Daliani, D., Eisenberger, M., Figg, W. D., Freidlin, B., Halabi, S., Hudes, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3461 · Cited by 977
A population-based study of cardiovascular disease mortality risk in US cancer patients
Sturgeon, K. M., Deng, L., Bluethmann, S. M., Zhou, S., Trifiletti, D. M., Jiang, C., Kelly, S. P., & Zaorsky, N. G. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz766 · Cited by 923
Schally, A. V., Arimura, A., Kastin, A. J., Matsuo, H., Baba, Y., Redding, T. W., Nair, R. M. G., Debeljuk, L., & White, W. F. (1971) · Science · doi:10.1126/science.173.4001.1036 · Cited by 770
Keating, N. L., O'Malley, A. J., Freedland, S. J., & Smith, M. R. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp404 · Cited by 622
Klotz, L. H., BOCCON-GIBOD, L., Shore, N. D., Andreou, C., Persson, B., Cantor, P., Jensen, J.-K., Olesen, T. K., & Schröder, F. H. (2008) · British Journal of Urology · doi:10.1111/j.1464-410x.2008.08183.x · Cited by 614
Self-citationIntermittent Androgen Suppression for Rising PSA Level after Radiotherapy
Crook, J. M., O'Callaghan, C. J., Duncan, G., Dearnaley, D. P., Higano, C. S., Horwitz, E. M., Frymire, E., Malone, S., Chin, J., Nabid, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201546 · Cited by 499
Self-citationGONADOTROPIN-RELEASING HORMONE AND ITS ANALOGS
Conn, P. D., & Crowley, W. F. (1994) · Annual Review of Medicine · doi:10.1146/annurev.med.45.1.391 · Cited by 459
Cardiovascular Morbidity Associated with Gonadotropin Releasing Hormone Agonists and an Antagonist
Albertsen, P. C., Klotz, L., Tombal, B., Grady, J., Olesen, T. K., & Nilsson, J. (2014) · European Urology · doi:10.1016/j.eururo.2013.10.032 · Cited by 341
Self-citationHormonal therapy: historical perspective to future directions
McLeod, D. G. (2003) · Urology · doi:10.1016/s0090-4295(02)02393-2 · Cited by 155
Zietman, A. L., Prince, E. A., Nakfoor, B. M., & Park, J. J. (1997) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(97)00309-x · Cited by 141
Effects of Gonadotrophin‐Releasing Hormone Outside the Hypothalamic‐Pituitary‐Reproductive Axis
Skinner, D. C., Albertson, A. J., Navratil, A. M., Smith, A. S., Mignot, M., Talbott, H. A., & Scanlan‐Blake, N. (2009) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2009.01842.x · Cited by 119
Miwa, K., Hitaka, T., Imada, T., Sasaki, S., Yoshimatsu, M., Kusaka, M., Tanaka, A., Nakata, D., Furuya, S., Endo, S., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200216q · Cited by 109
Recent trends in the management of advanced prostate cancer
Ritch, C. R., & Cookson, M. S. (2018) · F1000Research · doi:10.12688/f1000research.15382.1 · Cited by 104
Self-citationHopmans, S., Duivenvoorden, W., Werstuck, G. H., Klotz, L. H., & Pinthus, J. H. (2014) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2014.06.018 · Cited by 83
Dearnaley, D. P., Saltzstein, D. R., Sylvester, J. E., Karsh, L. I., Mehlhaff, B. A., Pieczonka, C. M., Bailen, J. L., Shi, H., Ye, Z., Faessel, H. M., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.03.001 · Cited by 76
Self-citationNakata, D., Masaki, T., Tanaka, A., Yoshimatsu, M., Akinaga, Y., Asada, M., Sasada, R., Takeyama, M., Miwa, K., Watanabe, T., et al. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.12.001 · Cited by 75
MacLean, D. B., Shi, H., Faessel, H. M., & Fred Saad, C. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2770 · Cited by 73
Knutsson, A., Hsiung, S., Celik, S., Rattik, S., Mattisson, I. Y., Wigren, M., Scher, H. I., Nilsson, J. Å., & Hultgårdh‐Nilsson, A. (2016) · Scientific Reports · doi:10.1038/srep26220 · Cited by 54
Adjuvant androgen deprivation therapy for prostate cancer treated with radiation therapy
Siddiqui, Z. A., & Krauss, D. J. (2018) · Translational Andrology and Urology · doi:10.21037/tau.2018.01.06 · Cited by 54
The role of LHRH antagonists in the treatment of prostate cancer.
Crawford, E. D., & Hou, A. H. (2009) · PubMed · Cited by 43
Oh, W. K., Landrum, M. B., Lamont, E. B., McNeil, B. J., & Keating, N. L. (2009) · Urology · doi:10.1016/j.urology.2009.08.008 · Cited by 37
Behl, A. S., Ellis, L., Pilon, D., et al. (2017) · PubMed · Cited by 37
Lafeuille, M., Grittner, A. M., Lefèbvre, P., Ellis, L., McKenzie, R. S., Slaton, T. L., & Kozma, C. M. (2014) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2014.20.5.477 · Cited by 35
Fred Saad, C., Bailen, J. L., Pieczonka, C. M., Saltzstein, D. R., SIEBER, P. R., MacLean, D. B., Shi, H., Faessel, H. M., & Shore, N. D. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.2_suppl.200 · Cited by 30
Self-citationThomsen, F. B., Sandin, F., Garmo, H., Lissbrant, I. F., Ahlgren, G., Hemelrijck, M. V., Adolfsson, J., Robinson, D., & Stattin, P. E. (2017) · European Urology · doi:10.1016/j.eururo.2017.06.036 · Cited by 29
Risk of Testosterone Flare in the Era of the Saturation Model: One More Historical Myth
Krakowsky, Y., & Morgentaler, A. (2017) · European Urology Focus · doi:10.1016/j.euf.2017.06.008 · Cited by 28
Risk of disease flare with LHRH agonist therapy in men with prostate cancer: Myth or fact?
Vis, A. N., van der Sluis, T. M., Al-Itejawi, H. H. M., van Moorselaar, R. J. A., & MEULEMAN, E. J. H. (2014) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2014.04.016 · Cited by 24
Cited by
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac244 · Cited by 3,076
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeac106 · Cited by 507
Hormonal Therapy for Prostate Cancer
Desai, K., McManus, J. M., & Sharifi, N. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab002 · Cited by 447
Tilki, D., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Brunckhorst, O., Darraugh, J., Eberli, D., De Meerleer, G., De Santis, M., Farolfi, A., et al. (2024) · European Urology · doi:10.1016/j.eururo.2024.04.010 · Cited by 352
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
He, Y., Xu, W., Xiao, Y.-T., Huang, H., Gu, D., & Ren, S. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01042-7 · Cited by 261
Metadata
- Authors
- Shore, N. D., Saad, F., Cookson, M. S., George, D. J., Saltzstein, D. R., Tutrone, R., Akaza, H., Bossi, A., van Veenhuyzen, D. F., Selby, B., Fan, X., Kang, V., Walling, J., & Tombal, B.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-06-04
- Volume
- 382
- Issue
- 23
- Pages
- 2187-2196
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3032046986
- Cited by
- 444
- References
- 31
- FWCI
- 32.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.